Genmab A/S (GMAB) has commenced a public offering of 27,800,000 ADSs, representing 2,780,000 ordinary shares.
Underwriters over-allotment is an additional 4,170,000 ADSs.
Net proceeds will be used for the development of its product candidates and to continue pre-commercial activities.
Pricing of the offering is expected during the week commencing on July 15.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.